戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 e effects found for exogenously administered adenosine agonists.
2 eta, IL-6, and IL-8 mRNA were not changed by adenosine agonists.
3                                          The adenosine agonist 2-phenylaminoadenosine (PAD) stimulate
4 bstituted adenosines designed from the A(2B) adenosine agonist 4 were synthesized and their A(2B)R po
5                             The nonselective adenosine agonist 5'-N-ethylcarboxamidoadenosine (NECA)
6 ulated with IL-1 and either the nonselective adenosine agonist 5'-N-ethylcarboxamidoadenosine (NECA)
7 treatments in the presence and absence of an adenosine agonist and antagonist.
8 f this study was to determine the effects of adenosine agonists and an antagonist on ischemia-induced
9 imulation frequencies and in the presence of adenosine agonists and antagonists.
10 f ICB CHA suggesting cross-tolerance between adenosine agonists and cannabinoids.
11 lls and primary neurons after treatment with adenosine agonists and PACAP.
12             Previous studies have shown that adenosine agonists are effective in reducing intraocular
13                                        While adenosine agonists cause profound hypothermia via each A
14 osine receptor agonist NECA but not the A(1)-adenosine agonist CCPA replicated the adenosine effect.
15   These effects were reproduced by using the adenosine agonist CGS 21680 and were counteracted with t
16              These data demonstrate that the adenosine agonist CHA lowers IOP in a dose-related fashi
17           These studies demonstrate that the adenosine agonist CHA significantly increases convention
18 hod for determining specificity of synthetic adenosine agonist compounds for the A2A and A2B receptor
19 and allowing us to isolate the most specific adenosine agonist compounds.
20                                              Adenosine agonist concentrations that abrogated cytokine
21  liquid culture gave ED50 values for various adenosine agonists consistent with reported Kd alpha val
22        Contrary to expectations, neither the adenosine agonists (CPA, propentofylline) nor the antago
23  Adenosine and dipyridamole are nonselective adenosine agonists currently used as pharmacologic stres
24  with the ocular hypotensive response to the adenosine agonist cyclohexyladenosine (CHA).
25                                              Adenosine agonist-dependent growth response of yeast str
26 alent linking of functionalized congeners of adenosine agonists, each being selective for either the
27  highlights the potential therapeutic use of adenosine agonists for treating autoimmune diseases invo
28     While simple carbocyclic substitution of adenosine agonists greatly diminishes potency, methanoca
29                                      Because adenosine agonists have antiinflammatory effects, and be
30 affinity of ribose-containing ligands (i.e., adenosine agonists) have been identified in both TM3 and
31 ng apical as well as basolateral delivery of adenosine agonists in varying renal preparations.
32 of Gly-14 in TM1 to Thr-14, the affinity for adenosine agonists increased 100-fold, and after Pro-25
33 ylate (BTH4, 7; Figure 1), which antagonized adenosine agonist-induced inhibition of adenylyl cyclase
34 receptors and mechanisms responsible for the adenosine agonist-induced rise in IOP.
35  with a KB value of 1.62 +/- 0.73 microM and adenosine agonist-induced stimulation of adenylyl cyclas
36                                              Adenosine agonists inhibit TNF-alpha production in macro
37             Previous studies have shown that adenosine agonists may induce a rise in intraocular pres
38 timulated CGRP release and suggest that A(1) adenosine agonists may warrant further investigation in
39 erebellar administration of the A1-selective adenosine agonist, N6-cyclohexyladenosine (CHA) on ethan
40                                          The adenosine agonist NECA (100 micromol/L) increased interl
41  receptor transcripts, only the nonselective adenosine agonist NECA (5'-N-ethylcarboxamidoadenosine),
42       The ocular effects of the nonselective adenosine agonist NECA, the relatively selective adenosi
43   Activation of the current by serotonin and adenosine agonists occurred with a time constant of 200-
44                                              Adenosine agonists or adenosine regulating agents have p
45               The stimulatory actions of the adenosine agonist PIA on IR-beta-EP release and on cAMP
46                                              Adenosine agonists reduced IPSCs with the following rank
47 (-7) M), but only in the presence of PIA, an adenosine agonist that inhibits the cyclic AMP pathway.
48             After a 20-min treatment with an adenosine agonist, the desensitization of A2a and A2b re
49          High affinity binding sites for A2a adenosine agonists were detected in yeast membranes cont